Events1st International Electronic Conference on Molecular Sciences: Druggable Targets of Emerging Infectious Diseases
Published
This submission belongs to the session S2. Pathogens for Humans and Multidrug Resistance: the Great Challenge to Win of the event 1st International Electronic Conference on Molecular Sciences: Druggable Targets of Emerging Infectious Diseases
Published date
31 Aug, 2021
Academic Editor
author-avatarClemente Capasso
Citation
Luisa Chocarro, Ester Blanco, Hugo Arasanz, Ana Bocanegra, Leticia Fernández Rubio, Miriam Echaide, Maider Garnica, Pablo Ramos, Grazyna Kochan, David Escors, LAG-3 role in infection, in Proceedings of 1st International Electronic Conference on Molecular Sciences: Druggable Targets of Emerging Infectious Diseases, 1 September–14 September 2021, MDPI: Basel, Switzerland, doi: 10.3390/ECMS2021-10835
Share
Email
Facebook
Twitter
LinkedIn

LAG-3 role in infection

Hugo Arasanz 2,3
Maider Garnica 2
1. OncoImmunology Unit, Navarrabiomed-Fundacion Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdISNA), Pamplona, Navarra, Spain, Spain
2. Oncoimmunology Group, Navarrabiomed-Fundacion Miguel Servet, Universidad Pública de Navarra, IdISNA, Irunlarrea 3, 31008 Pamplona, Navarra, Spain
3. Department of Medical Oncology, Complejo Hospitalario de Navarra CHN-IdISNA, 31008 Pamplona, Navarra, Spain
Abstract

Lymphocyte activation gene 3 (LAG-3) is a cell surface inhibitory receptor with multiple biological activities over T cell activation and effector functions. LAG-3 plays a regulatory role in immunity and emerged some time ago as an inhibitory immune checkpoint molecule.

A systematic research was performed using the PubMed and ClinicalTrial.gov databases. Articles published up to 2021 meeting the inclusion criteria were investigated. LAG-3 expression has been linked to increased pathology in certain infections, such as the ones caused by Salmonella, Plasmodium parasites, Mycobacterium tuberculosis, human immunodeficiency virus (HIV), non-pathogenic simian immunodeficiency virus (SIV), in hepatitis B virus (HBV), human papillomavirus (HPV), chronic hepatitis C virus (HCV), lymphocytic choriomeningitis virus (LCMV) and herpes simplex virus 1 (HSV-1).

Here, we will discuss the impaired control of cell-mediated immunity associated with high accumulation of LAG-3 after infection, in most cases associated with a high bacterial/viral load, a reduced survival rate or persisting metabolic and inflammation disorders. Interestingly, the in vitro blockade of PD-1/LAG-3 interactions enhanced cytokine production in response to some of these infections.

Keywords
LAG-3
Immune Checkpoint
Manuscript
Poster
ECMS Poster Luisa Chocarro.pdf
Morphological and biochemical value of nephrotoxic effects of doxorubicin and PLGA-doxorubicin
F- and OH-containing isopulegol-derived octahydro-2H-chromenes as agents against influenza A virus